Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients

Shujuan Ma, MM; Yixiang Zheng, MM; Yanni Xiao, MM; Pengcheng Zhou, MM; Hongzhuan Tan, PhD

Abstract
Metformin has garnered more interest as a chemo-preventive agent given the increased liver cancer risk in diabetic patients. This work was undertaken to better understand the effect of metformin use on liver cancer risk in diabetic patients.

A comprehensive literature search was performed in PubMed, Embase, BIOSIS Previews, Web of Science, and Cochrane Library through July 30, 2016. Meta-analyses were performed using Stata version 12.0, with odds ratio (ORs) and 95% confidence intervals (CIs) as effect measures.

Twenty-three studies were included. Meta-analysis of 19 studies involving 550,882 diabetic subjects suggested that metformin use reduced the ratio of liver cancer by 48% (OR = 0.52; 95% CI, 0.40–0.68) compared with nonusers. The protective effect was validated in all the exploratory subgroup analyses, except that pooled result of post hoc analyses of 2 randomized controlled trials found no significant difference between subjects with metformin and those without, with OR being 0.84 (95% CI, 0.10–6.83). After adjusting for hepatitis B/C virus infection, cirrhosis, obesity, behavioral factors, and time-related bias, the association was stable, pooled OR ranged from 0.42 to 0.75.

A protective effect for liver cancer was found in diabetic metformin users. However, more randomized clinical evidence is still needed to verify the results.

Abbreviations: ADM = antidiabetic medication, AMPK = adenosine monophosphate-activated protein kinase, CI = confidence interval, DM = diabetes mellitus, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, HR = hazard ratio, OR = odds ratio, RCT = randomized controlled trial, RR = relative risk.

Keywords: diabetes mellitus, liver cancer, meta-analysis, metformin

1. Introduction
Liver cancer is the fifth most common cancer worldwide and the third-leading cause of cancer related-death.[1] Diabetes mellitus (DM) is becoming an established independent risk factor for liver cancer as reported in multiple observational studies and subsequent meta-analyses.[2–4] In these existing studies, DM has been reported to confer a 2- to 4-fold risk of liver cancer, and the risk increases with DM severity and duration. However, this risk may be mitigated by antidiabetic medications (ADMs). Metformin, a widely used ADM, has recently attracted great attention for its role in reducing the risk of liver cancer through both insulin-dependent and insulin-independent mechanisms.[4] However, the evidence for a cancer preventive effect for metformin has not been consistently demonstrated.

Association of metformin and risk of liver cancer are mainly studied in animal and observational human studies. A meta-analysis demonstrated that metformin appeared to have a direct antihepatocellular carcinoma (HCC) effect in animal models.[5] Accumulating epidemiologic studies comparing the risk of liver cancer between those using metformin with those using other ADMs have shown somewhat variable results,[6–9] and it was also endorsed that confounders were not well addressed in most studies.[10] Several meta-analyses have been published to determine if a consistent effect of metformin use on liver cancer incidence was evident.[10–13] Except for the incomplete included studies, meta-analyses in previous reviews were rough, and the heterogeneity was not explored in detail.

In our opinion, the differences in estimates and the heterogeneity between studies could largely be explained by differences in study designs, quality, population, the comparators used, estimation of the exposure to metformin (duration and dosage) and adjusted factors, as the inability to account for these factors may result in certain degrees of bias. To better understand the association of metformin and risk of liver cancer, we embarked on a systematic review and meta-analysis with integrated overall, subgroup and sensitivity analyses.

2. Methods
2.1. Inclusion criteria
Either observational studies (cohort and case–control studies) or post hoc analyses of randomized controlled trials (RCTs) were included if they evaluated and defined exposure to metformin or
biguanide, reported liver cancer incidence or related outcomes of diabetic patients, provided effective comparison groups, and reported hazard ratio (HR)/relative risk (RR)/odds ratio (OR) and corresponding 95% confidence intervals (CIs), or provided sufficient data for their estimations. Inclusion was not restricted by language, study size, or publication type. The most recent or most comprehensive report was given precedence if there were multiple publications (regardless of study design) from the same population, while the others might be included in subgroup analysis according to the concrete conditions.

2.2. Literature search

A comprehensive literature search was performed in PubMed, Embase, BIOSIS Previews, Web of Science, Cochrane Library, National Institutes of Health database, EU clinical trials register from the earliest date available through July 30, 2016, without any restrictions. In order to include more potential literature, our overall search strategy only included terms for metformin and liver cancer. The comprehensive literature search was conducted as follow: ((liver cancer) OR (liver carcinoma) OR (liver neoplasm) OR (liver tumor) OR (hepatoma) OR (hepatocellular carcinoma) OR (HCC) OR (hepatic cancer) OR (hepatic neoplasm) OR (hepatic tumor) OR (cholangiocarcinoma)) AND ((metformin) OR biguanide). We screened bibliographies of selected original studies, review articles, and relevant conference abstracts. Attempts were made to contact the corresponding authors for additional data.

2.3. Data extraction

Citations were merged together in Endnote, version X7 to facilitate management. Two authors independently applied the inclusion criteria to all retrieved articles in an unblinded standardized manner, evaluated by title, abstract, and full text. For each of eligible study, information of first author, publication year, location, study design, data source, study period, mean follow-up, characteristics of study population (mean age, sex ratio), definition of exposure and control, dose and duration of exposure (if reported), comparison groups, risk estimates (included HR, RR, OR), and 95% CIs with and without adjustment for confounding factors were selectively extracted onto piloted structured forms independently by 2 authors. As subjects in most studies used combination therapy, the final analysis on exposure used the dichotomous categorical variable of “with” or “without” use of metformin.

Adjusted factors were extracted, and some of them were selected for further analysis: infected with hepatitis B virus (HBV) or hepatitis C virus (HCV), cirrhosis, obesity (including body mass index and obesity), behavioral factors (including alcohol abuse and cigarette smoking), use of statins, and time-related bias, given their modifying effects on metformin’s activity on DM and liver cancer risk. Publication bias was detected for overall analysis using Begg test and Egger test (publication bias considered present if

2.5. Statistical analysis

Adjusted estimate was mainly used for quantitative analysis. Crude estimate served as an alternative in case of no adjusted estimate was available. When estimates or 95% CIs were missing or incomplete, appropriate summary statistics or Kaplan–Meier curves were used to calculate based on published methods. OR was employed as a common measure of the association between metformin use and liver cancer risk due to the enrollment of case–control studies in most analyses. Between-study heterogeneity was qualitatively assessed by using Cochrane Q test with a significance level of $P < .1$, and quantified by estimated $I^2$ ($I^2 < 50\%$ representing low heterogeneity, $50\% \leq I^2 \leq 75\%$ representing moderate heterogeneity, $I^2 > 75\%$ representing substantial heterogeneity). An inverse variance fixed-effects model was used to calculate when the test for heterogeneity was not statistically significant, otherwise the DerSimonian–Laird random-effects model was employed.

Sensitivity analyses were performed to assess the robustness of results. Between-study sources of heterogeneity were further investigated using subgroup analyses by stratifying original estimates according to study characteristics (study design, setting, and quality), controlled ADM, and adjustment. Analyses of adjusted estimates were emphasized on studies controlling for HBV/HCV infection, cirrhosis, obesity, behavioral factors, use of statins, and time-related bias, given their modifying effects on metformin’s activity on DM and liver cancer risk. Publication bias was detected for overall analysis using Begg test and Egger test (publication bias considered present if $P < .1$). All the statistical analyses were 2-sided and performed using Stata version 12.0 (StataCorp, College Station, TX).

3. Results

3.1. Description of included studies

Searches identified 2389 potentially relevant studies. The selection process is shown in Fig. 1. Twenty-three studies fulfilled the inclusion criteria and were included in the meta-analysis (2 RCTs, 11 cohort studies, 10 case–control studies). These 23 studies cumulatively reported more than 35,000 cases of liver cancer in 663,335 diabetic subjects. Only 19 studies were included in the overall analysis, and 3 control studies in most analyses. Between-study sources of heterogeneity were further investigated using subgroup analyses by stratifying original estimates according to study characteristics (study design, setting, and quality), controlled ADM, and adjustment. Analyses of adjusted estimates were emphasized on studies controlling for HBV/HCV infection, cirrhosis, obesity, behavioral factors, use of statins, and time-related bias, given their modifying effects on metformin’s activity on DM and liver cancer risk. Publication bias was detected for overall analysis using Begg test and Egger test (publication bias considered present if $P < .1$). All the statistical analyses were 2-sided and performed using Stata version 12.0 (StataCorp, College Station, TX).
The characteristics of included studies are shown in Table 1. Twelve studies were population-based studies, and the remainder were hospital-based studies. Overall methodological quality of included studies was high. Treatment comparators were sulfonylureas or nonuse of any ADMs. Use of statins, and when the controlled drugs were de

3.2. Overall analysis

On the basis of 19 studies involving 550,882 diabetic patients, compared with metformin nonusers, metformin use reduced the ratio of liver cancer by 48% (OR = 0.52; 95% CI, 0.40–0.68; P < .001), with substantial heterogeneity (I² = 83.7%) (Fig. 2). Sensitivity analysis using leave-one-out method found that the pooled result was robust when omitting any one study alone, heterogeneity kept substantial except when omitting the study with maximum weight from overall analysis, I² dropped to 33.5%, with the summary OR being 0.53 (95% CI, 0.44–0.63; P < .001). Significant publication bias was found for overall analysis by Begg test (P = .069) and Egger test (P < .001).

3.3. Subgroup analysis

Subgroup analyses were conducted to further validate the result from overall analysis, and to explore potential sources of heterogeneity among studies (Table 2). Hierarchies of study setting, quality, controlled drugs, and adjustment did not change over the significant reduction in ratio of liver cancer in metformin users. Pooled result of post hoc analyses of 2 RCTs found no significant difference between subjects with metformin and those without, with OR being 0.84 (95% CI, 0.10–6.83; P = .871) (Fig. 2). Subgroup analyses of hospital-based studies with relatively small sample size (OR = 0.32; 95% CI, 0.24–0.44) or studies with low quality (OR = 0.29; 95% CI, 0.18–0.49) showed an exaggeration in metformin’s effect. Metformin showed higher protective effect of liver cancer when compared with insulin (OR = 0.36; 95% CI, 0.25–0.51), other than sulfonylurea (OR = 0.65; 95% CI, 0.55–0.78) and nonuser of any ADM (OR = 0.62; 95% CI, 0.40–0.98). Furthermore, use of adjusted estimates caused numerical increases on pooled OR and heterogeneity. Compared to the analysis of all adjusted estimates (OR = 0.57; 95% CI, 0.42–0.76; P < .001), numerical increases in the ratio of liver cancer in metformin users were found when the estimates were adjusted for HBV/HCV infection, cirrhosis, obesity, and behavioral factors (pooled ORs ranged from 0.42 to 0.51), while the ratio reduction decreased in studies adjusted for use of statins (OR = 0.75; 95% CI, 0.68–0.83; P < .001) and time-related bias (OR = 0.65; 95% CI, 0.48–0.89; P = .006).

Heterogeneity was significant in most subgroups, with I² (>) ranging from 50.5% to 89.2% (Table 2). Nevertheless, no heterogeneity was found in the subgroup analyses of hospital-based studies (I² = 0%) and studies with low quality (I² = 0%). Moreover, for subgroup analyses of RCTs, studies adjusted for use of statins, and when the controlled drugs were definitely restricted to insulin, sulfonylurea, or nonuser of any ADM, heterogeneity was limited (I² ranged from 14.0% to 39.5%).

4. Discussion

This systematic review synthesized evidence on association between use of metformin and risk of liver cancer in diabetic patients from 23 studies. We used systematic strategy and broad search terms in multiple databases to identify as many studies as possible. Rigorous methods were used to extract and appraise the data. Multiple publications from the same population were checked in any analysis. Considering the potential confounding factors for liver cancer, adjusted estimates were used instead of the unadjusted ones as much as possible to make the summary results more precise and plausible.

Overall meta-analysis of 19 studies involving 550,882 diabetic subjects found that, relative to nonuser, use of metformin reduced the ratio of liver cancer by 48% (OR = 0.52; 95% CI, 0.40–0.68; P < .001), with substantial heterogeneity (I² = 83.7%). Sensitivity analysis found that the heterogeneity was mainly from a high-quality population-based study, which might be largely limited by the fewer available studies (n = 2). Actually, most RCTs are not designed or sufficiently powered to examine cancer outcomes due to the short follow-up periods and very few cancer events.
| Study (year) | Design | NOS score | Location | Study population | Total subject | Mean age, y | Sex, % male | Liver cancer cases | Data source | Time period | Mean follow-up, y | Definition of exposure and control | Adjusting factors |
|-------------|--------|-----------|----------|------------------|--------------|-------------|-------------|-------------------|-------------|-------------|-----------------|-----------------------------------|--------------------|
| Home 2010 (ADOPT) | RCT | 6 | USA, Canada, Europe | Diabetic subjects | 4351 | 56.8 | 57.7 | 4 | 4 | Post hoc analysis | April 2000–June 2006 | Ex: metformin ≤ 2 g/d; Con: rosiglitazone ≤ 8 mg/d, glyburide/bendamidine ≤ 15 mg/d | Study exposure |
| Home 2010 (RECORD) | RCT | 6 | Europe, Australia | Diabetic subjects | 4447 | 58.4 | 51.6 | 4 | 4 | Post hoc analysis | April 2001–December 2008 | Ex: metformin ≤ 2.55 g/d and sulfonylureas/rosiglitazone; Con: sulfonylureas and rosiglitazone | Study exposure |
| Oliveira 2006 | Cohort | 9 | USA | Diabetic subjects | 191,223 | 56.0 | 51.0 | 11 | Insured population | January 2000–December 2004 | Ex: metformin (Kild h ≥ 1 prescription); Con: without metformin (did not fill any prescription) | Age, sex, hepatitis B, hepatitis C, cirrhosis, alcoholism |
| Nontschou 2011 | Cohort | 7 | France | Diabetics with HCV cirrhosis | 100 | 61.0 | 53.0 | 39 | Screening program | January 1988–January 2007 | Ex: with metformin (filled ≥ 1 prescription); Con: without metformin (did not fill any prescriptions) | Age, sex, cirrhosis, alcohol abuse, hepatitis B, hepatitis C, other biochemical index |
| Ampuero 2012 | Cohort | 2 | Spain | Diabetic subjects | 82 | 57.0 | 71.0 | 9 | NR | NR | NR | Ex: metformin monotherapy or metformin plus insulin; Con: diet alone, insulin secretagogues; insulin therapy | NA |
| Hei 2012 | Cohort | 7 | China | Diabetic subjects | 10,786 | 61.2 | 52.2 | 220 | Taiwan’s NNH | 2000–2008 | Ex: metformin monotherapy; Con: sulfonylurea monotherapy, insulin monotherapy | Age, sex |
| Bové 2012 | Cohort | 8 | China | Diabetic subjects | 19,349 | 56.5 | 57.8 | 224 | Taiwan’s NNH | 2000–2005 | Ex: with metformin; Con: without metformin | Age, sex, cirrhosis, alcohol abuse, hepatitis B, hepatitis C |
| Ruiter 2012 | Cohort | 7 | The Netherlands | Diabetic subjects | 85,289 | 63.3 | 47.1 | 31 | PHARMO RLS | January 1988–December 2008 | Ex: metformin; Con: sulfonylurea derivatives | Age, sex, smoking status, alcohol consumption, aspirin/NSAIDs, statins, BMI, DM duration, HbA1c, other biochemical index |
| Aydin 2013 | Cohort | 5 | Turkey | Diabetic subjects | 665 | 57.2 | 42.0 | 2 | Duzce University | January 2010–January 2011 | Ex: metformin monotherapy; Con: without metformin; insulin monotherapy | NA |
| Hsu 2014 | Cohort | 4 | China | Diabetics received NUC for CHB with liver cirrhosis | 49 | 52.8 | 73.3 | 13 | E-Da hospital | September 2007–March 2013 | Ex: with metformin; Con: without metformin | Age, sex |
| Tsilidis 2014 | Cohort | 9 | UK | Diabetic subjects | 95,820 | 62.1 | 56.5 | 102 | CPRD | January 1987–December 2010 | Ex: with metformin; metformin monotherapy; Con: without metformin; sulfonylureas monotherapy | Age, sex, smoking status, alcohol consumption, aspirin/NSAIDs, statins, BMI, DM duration, HbA1c, year of first ADM prescription, year of first OGLD prescription, number of hospitalizations and drugs |
| Lin 2015 | Cohort | 9 | China | Diabetic subjects | 34,823 | 54.3 | 50.7 | 285 | Taiwan’s NNH | 2005–2010 | Ex: with metformin; Con: without metformin | Age, sex, cirrhosis, alcohol abuse, hepatitis B and C, dyslipidemia, gout, duration of ADM exposure |
| Valent 2016 | Cohort | 7 | Italy | Diabetic subjects | 109,255 | NR | NR | NR | Regional health information system | January 2002–December 2014 | Ex: with metformin; Con: without metformin | Age at start of observation, sex, time-dependent variable, other drugs |
| Donatini 2016 | Case-control | 5 | Italy | Diabetic HCC, liver cirrhosis, and controls (general population) | 595 | 68.3 | 80.0 | 190 | Pondicherry General Hospital | January 1994–December 2008 | Ex: metformin; Con: sulfonylureas, insulin | Age, sex, BMI, HBV and HCV infection, alcohol abuse, ALT level, triglycerides, cholesterol and DM duration | (continued) |
### Table 1 (continued)

| Study (year) | Design | NOS score | Location | Study population | Total subject | Mean age, y | Sex, % male | Liver cancer cases | Data source | Time period | Ex | Definition of exposure and control | Adjusting factors |
|--------------|--------|-----------|----------|------------------|---------------|-------------|-------------|-------------------|-------------|-------------|----|---------------------------------|------------------|
| Hassan 2010 | Case-control | 7 | USA | Diabetic HCC and controls (healthy spouses or in-laws of specific cancer patients) | 208 | 60.8 | 74.5 | 122 | M. D. Anderson Cancer Center | January 2000–July 2006 | NA | Ex: with biguanide; Con: without biguanide | Age, sex, educational level, smoking, alcohol drinking, HCV, HBV, family history of cancer, Age, sex |
| Chiang 2012 | Case-control | 6 | Japan | Diabetic HCC and non-HCC (both were hepatitis C patients) | 241 | 67.0 | 67.6 | 138 | Kurume Nagata and Chikugo Hospital | January 2004–December 2008 | NR | Ex: with biguanide; Con: without biguanide | Age, sex, chronic liver disease, other ADMs, statins, aspirin, other drugs, and diseases Match: age ≤55 y, age, sex, ethnicity, residence |
| Chatteriaki 2013 | Case-control | 7 | USA | Diabetic ICC and controls (biobank participants) | 52,588 | 66.7 | 63.9 | 10,741 | Taiwan's NHI | January 2000–December 2007 | 7.9 | Ex: with metformin; Con: without metformin | Age, sex, educational level, smoking, alcohol drinking, HBV, family history of cancer, Age, sex |
| Chen 2015 | Case-control | 7 | China | Diabetic HCC and controls (randomly sampled subjects) | 47,820 | 62.5 | 72.8 | 22,047 | Taiwan's NHI | January 1997–December 2008 | NA | Ex: with metformin; Con: without metformin | Age, sex, hepatitis B and C, liver cirrhosis, end-stage renal disease, DM duration, DM control and other ADMs, Age, sex, calendar time, general practice, BMI, smoking, alcohol-related disorders, HCV, and other ADMs and drugs, DM duration, Charlson comorbidity index, other ADMs and drugs, and other ADMs and drugs |
| Husberg 2016 | Case-control | 8 | U.K. | Diabetic liver cancer and controls (same study population) | 1069 | 69.6 | 84.1 | 234 | CPRD | 1986–2011 | NR | Ex: with metformin; Con: without metformin | Age, sex, calendar time, general practice, BMI, smoking, alcohol-related disorders, HCV, and other ADMs and drugs, DM duration, Charlson comorbidity index, other ADMs and drugs, and other ADMs and drugs |
| Bovetti 2015 | Case-control | 7 | Italy | Diabetic HCC and controls (diabetes mellitus and age at risk of developing HCC) | 3962 | 65.3 | 75.2 | 190 | Healthcare utilization databases | January 2006–December 2007 | 6.0 | Ex: with metformin; Con: without metformin | Age, sex, date at cohort entry, statins, duration of follow-up, Charlson comorbidity index, other ADMs and drugs, and other ADMs and drugs |
| Mele 2015 | Case-control | 5 | Italy | Diabetic HCC and controls (out-patients, patients undergoing surgical interventions) | 121 | NR | NR | 69 | Agostino Gemelli Hospital | January 2005–July 2012 | NA | Ex: with metformin; Con: without metformin | Age, sex, tobacco smoking, alcohol drinking |
| Ueyama 2016 | Case-control | 3 | Japan | Diabetic HCC and controls (included patients with liver cirrhosis) | 389 | 70.9 | 51.7 | 59 | Five hospitals | NR | NA | Ex: with metformin; Con: without metformin | NA |

**Exposure with metformin, patients who ever had metformin, including metformin-combined therapy; without metformin, patients who had no metformin, but might have no medication, or have used diet alone or other ADMs.**

**ADM** = antidiabetic medication, **ADOPT** = A Diabetes Outcome Progression Trial, **AFP** = alpha-fetoprotein, **ALT** = alanine aminotransferase, **BMI** = body mass index, **CHB** = chronic hepatitis B, **Con = control**, **CPRD** = Clinical Practice Research Datalink, **DM** = diabetes mellitus, **Ex = exposure**, **HbA1c** = glycated hemoglobin, **HIV** = hepatitis B virus, **HCC** = hepatocellular cancer, **HCV** = hepatitis C virus, **ICC** = intrahepatic cholangiocarcinoma, **NA = not applied**, **NHI = National Health Insurance, NOS = Newcastle-Ottawa Scale, **NR = not reported, NEADS = nonsteroidal anti-inflammatory drugs, **NUC** = nucleoside analogue, **OSLD = oral glucose-lowering drug, RCT = randomized controlled trial, **RECORD** = Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes, **RLS** = record linkage system.

* Studies were only included in subgroup analyses.

*Subjects with at least 1 antidiabetic drug prescription.*
Metformin is one of the most commonly prescribed medications in the treatment of DM. However, DM treatment is a dynamic process, ADMs might be changed continuously and often used in combination, which made definition of exposure using dichotomous categorical variable of “with” or “without” use of metformin be somewhat less convincing. Thus we further subanalyzed supplemented comparisons between monotherapy of ADMs. Results showed that metformin had higher protective effect of liver cancer when compared with insulin, other than sulfonylurea and nonuser of any ADM. Beyond the plausible finding that use of insulin increased risk of liver cancer, another explanation is that metformin is a first-line ADM prescribed in less severe or shorter duration of DM, while insulin is usually prescribed to patients with longer duration and more advanced DM, which in turn may be associated with higher risk of liver cancer. However, when compared to nonuser of any ADM (mild or newly diagnosed DM patients), monotherapy use of metformin achieved a 38% (OR=0.62; 95% CI, 0.40–0.98) reduction in ratio of liver cancer, probably reflecting the real world scenario. Lots of confounders may have modifying effect on association between metformin and liver cancer risk in diabetic patients.

Presence of DM in patients with cirrhosis is an independent factor for the progression to liver cancer. Moreover, metformin may be specifically sensitive to certain etiological types of liver cancer. After adjusting for HBV/HCV infection, cirrhosis, obesity, and behavioral factors, the beneficial effects on the ratio of liver cancer for metformin use were significant and larger (pooled OR ranged from 0.42 to 0.51), which might be the true link between metformin use and liver cancer risk in diabetic patients. Recent reviews underscored the prevalence of time-related bias in observational studies, potentially leading to inflated estimates of metformin’s protective effect. Time-related bias includes immortal-time bias, time-window bias, and time-lag bias. Of note, exclusion of time-biased studies from our analysis resulted in a numerical decline on the ratio reduction (OR=0.65; 95% CI, 0.48–0.89; P=.006). Thus further studies should take these biases into account in the study design and analysis.

Statins was previously found to be associated with a reduced risk of liver cancer. Most of included studies did not take the concomitant use of statins into account to adjust for potential confounding. Subgroup analysis of studies adjusted for the use of
Several limitations of this study needed to be addressed and merited further discussion. First, significant heterogeneity was presented between studies in some of our analyses. However, sensitivity analyses found that the heterogeneity could be mostly interpreted by 1 same article. Except for the contribution of heterogeneity, omitting this article would not change over the initial results. Second, information on treatment was obtained through prescriptions contained in patients’ medical records, therefore a gap between prescribed and actual dose could bias the results. Third, adjustments of included studies might be incomplete and inconsistent. Although we performed subgroup analyses of adjusted estimates controlled for several important factors. Some other confounders were failed to control, such as information like details of DM (severity and duration) and metformin use (dose and duration) were absent in most studies, which would have been important to adjust for residual confounding. Fourth, significant publication bias was found for overall analysis. However, this might probably be the small-study effect rather than true publication bias, especially in the presence of significant heterogeneity among studies.

5. Conclusion

In conclusion, a protective effect in the risk of liver cancer was found in diabetic metformin users, and the protective effect was validated in most of our exploratory analyses. However, the conclusion should be interpreted with caution given the possibility of residual confounding. Simultaneously, limited by the observational nature allows only an association to be established. Plenty of experimental studies have added evidence to metformin’s protective effect on malignancies. Although the exact mechanism is not fully understood, several biologically plausible mechanisms have shown that metformin might have direct antiliver cancer activity by inhibiting proliferation and colony formation ability through adenosine monophosphate-activated protein kinase (AMPK) in HCC cells; suppressing HCC cell growth through induction of cell cycle G1/G0 phase arrest, p21CIP and p27KIP expression, and down-regulation of cyclin D1; inducing apoptosis in HCC cells via signaling pathways, including AMPK and p38 mitogen-activated protein kinase; and suppressing xenograft tumor growth in mouse models. Moreover, as an antihyperglycemic agent and insulin sensitizer, metformin treatment inhibits hepatic gluconeogenesis; reduces serum concentrations of insulin and insulin growth factor I, improves glycemic control, and decreases inflammatory response, thus leading to less aggressive behavior of cancer cells. However, given that not all in vitro and in vivo work with animal models could be successfully translated into clinical outcomes in humans, well-designed RCTs are still needed to provide authentic evidence.

### Table 2

| Subgroup | No. of studies | Total subject | Summary result | OR (95% CI) | P | I², % |
|----------|----------------|---------------|----------------|-------------|---|------|
| Design  |                |               |                |             |   |      |
| RCT      | 2              | 8798          | 0.84 (0.10–6.83) | 0.871 | 32.4 |
| Cohort   | 10             | 536,645       | 0.64 (0.48–0.86) | <0.003 | 83.9 |
| Case-control | 9         | 54,328        | 0.50 (0.36–0.70) | <0.001 | 74.1 |
| Setting  |                |               |                |             |   |      |
| Hospital-based | 12         | 11,161        | 0.32 (0.24–0.44) | <0.001 | 0  |
| Population-based | 7          | 539,721       | 0.69 (0.52–0.91) | 0.009 | 89.2 |
| Quality  |                |               |                |             |   |      |
| Low      | 6              | 1701          | 0.29 (0.18–0.49) | <0.001 | 0  |
| High     | 13             | 549,181       | 0.60 (0.45–0.79) | <0.001 | 86.1 |
| Controlled drugs |          |               |                |             |   |      |
| Insulin  | 6              | 11,100        | 0.36 (0.25–0.51) | <0.001 | 33.6 |
| Sulfonylurea | 4           | 160,115       | 0.65 (0.55–0.78) | <0.001 | 14.0 |
| Nonuse of any ADM | 3         | 785           | 0.62 (0.40–0.98) | 0.039 | 37.2 |
| Adjusted REs used or not |            |               |                |             |   |      |
| Unadjusted REs | 17        | 406,804       | 0.42 (0.36–0.49) | <0.001 | 0  |
| Adjusted REs  | 11           | 540,555       | 0.57 (0.42–0.76) | <0.001 | 88.8 |
| Adjustment |                |               |                |             |   |      |
| Infected with HBV/HCV | 8          | 247,226       | 0.50 (0.36–0.69) | <0.001 | 59.0 |
| Cirrhosis | 6              | 245,878       | 0.49 (0.34–0.69) | <0.001 | 50.5 |
| Obesity   | 4              | 131,338       | 0.51 (0.39–0.69) | <0.001 | 67.5 |
| Behavioral factors | 6           | 288,067       | 0.42 (0.24–0.75) | 0.003 | 66.0 |
| Use of statins | 3          | 152,370       | 0.75 (0.68–0.83) | <0.001 | 39.5 |
| Time-related bias | 7          | 320,844       | 0.65 (0.48–0.89) | 0.006 | 86.8 |

ADM = antidiabetic medication, CI = confidence interval, HBV = hepatitis B virus, HCV = hepatitis C virus, OR = odds ratio, RCT = randomized controlled trial, REs = risk estimates.
References

[1] Cancer. IARC. Cancer Incidence in Five Continents (CI5), Volume X. http://c5.iarc.fr/CI5-X; 2015.

[2] El-Serag HB, Hampa L, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80.

[3] Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012;130:1639-48.

[4] Morales DR, Morris AM, Morrish AD. Metformin in cancer treatment and prevention. Ann Rev Med 2015;66:17–29.

[5] Li J, Hernanda PY, Imer WM, et al. Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis. PLoS ONE 2013;10:e0127967.

[6] Bosetti C, Franchi M, Nicotra F, et al. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases. Pharmacoeconomics Drug Safety 2015;24:1-8.

[7] Lim CM, Huang HL, Chiu FY, et al. Association between gastroenterological malignancy and diabetes mellitus and anti-diabetic therapy: a nationwide, population-based cohort study. PLoS ONE 2015;10:e0123421.

[8] Mule L, Bosetti C, Turati F, et al. Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk. Gastroenterol Res Pract 2015;2015:570356.

[9] Valent F. Diabetes mellitus and the digestive organs: an Italian (CIN) population-based cohort study. J Diabetes Complications 2015;29:1056–61.

[10] Singh S, Singh PP, Singh AG, et al. Anti-diabetic drugs and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013;108:881–91.

[11] Zhang P, Li H, Tan X, et al. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013;37:207–18.

[12] Gandini S, Puntoni M, Heckman-Stoddard BM, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Rev 2014;17:867–85.

[13] Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2014;16:707–10.

[14] Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.

[15] Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol 2012;12:9.

[16] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ (Clin Res ed) 2003;327:557–60.

[17] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.

[18] Cabibbo G, Craxi A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2010;14:352–6.

[19] Sussa S, Auzaluy L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665–73.

[20] Saran U, Humar B, Kollo P, et al. Hepatocellular carcinoma and lifestyles. J Hepatol 2016;64:203–14.

[21] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088.

[22] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res ed) 1997;315:629–34.

[23] Egger M, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomized controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Routinized Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53:1838–45.

[24] Olivera SA, Koro CE, Ulickas Yoo M, et al. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr 2008;2:47–57.

[25] Nkongchou G, Cosmos E, Aout M, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011;96:2601–8.

[26] Ampuero J, Fernandez-Gil M, Nunez D, et al. Metformin treatment reduces hepatocellular carcinoma (HCC) risk in patients with cirrhosis C: a retrospective observational study of two independent cohorts. J Hepatol 2012;56:3240–1240.

[27] Li SY, Chen PC, Liao KF, et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012;107:46–52.

[28] Ruiter R, Visser LE, van Herk-Sukel MMP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives results from a large population-based follow-up study. Diabetes Care 2012;35:119–24.

[29] Aydin Y, Erden M, Ermis F, et al. Oral antidiabetics and insulin do not increase cancer risk. Acta Medica Mediterr 2013;29:859–67.

[30] Hsu YC, Wu CY, Lane HY, et al. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B. J Antimicrob Chemother 2014;69:1920–7.

[31] Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 2014;37:2522–32.

[32] Donadon V, Balbi M, Mas MD, et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010;30:750–8.

[33] Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010;116:1938–46.

[34] Kawaguchi T, Taniguchi E, Morita Y, et al. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 2010;30:479–86.

[35] Chancerelj R, Yang JD, Harmens WS, et al. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (Baltimore, MD) 2013;57:485–55.

[36] Ueyama M, Nishida N, Korneng M, et al. The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. J Gastroenterol 2016;51:370–9.

[37] Hsieh MC, Lee TC, Cheng SM, et al. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012;2012:413782.

[38] Chang CH, Lin JW, Wu LC, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology (Baltimore, MD) 2013;57:485–55.

[39] Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013;62:606–15.

[40] Hagberg WK, McGlynn KA, Sahasrabuddhe VV, et al. Anti-diabetic medications and risk of primary liver cancer in persons with type 2 diabetes. Br J Cancer 2014;111:1710–7.

[41] Lee MS, Hsu CC, Wahqvist ML, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11:20.

[42] Chiu CC, Huang CC, Chen YC, et al. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan. Intern Med 2013;52:99–46.

[43] Tseng CH. Diabetes is not an independent risk factor for hepatocellular carcinoma. Diabetes Metab Res Rev 2013;29:315–24.

[44] Chang C-H, Lin J-W, Wu L-C, et al. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:E1170–5.

[45] Wang SY, Chuang CS, Muo CH, et al. Metformin and the incidence of cancer in patients with diabetes: a nested case-control study. Diabetes Care 2013;36:e155–6.

[46] Chen HH, Lin MC, Muo CH, et al. Combination therapy of metformin and statin may decrease hepatocellular carcinoma among diabetic patients in Asia. Medicine 2015;94:e1013.

[47] Donadon V, Balbi M, Gheretti M, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2010;16:3025–32.

[48] Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17–30.
[50] Elkrief L, Rautou P-E, Sarin S, et al. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int 2016;36:936–48.
[51] Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013;144:323–32.
[52] Ampuero J, Romero-Gomez M. Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: role of statins and metformin. World J Hepatol 2015;7:1105–11.
[53] Zheng LY, Zou DJ. Metformin inhibits proliferation and colony formation ability through AMP-activated protein kinase in hepatocellular carcinoma cells. Diabetes 2012;61:A457.
[54] Cai X, Hu X, Cai B, et al. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21cip and p27kip expression and downregulation of cyclin D1 in vitro and in vivo. Oncol Rep 2013;30:2449–57.
[55] Park DB. Metformin promotes apoptosis but suppresses autophagy in glucose-deprived H4IE hepatocellular carcinoma cells. Diabetes Metab J 2015;39:518–27.
[56] Liu J, Li M, Song B, et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 2013;31:264–70.
[57] Foretz M, Helvard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355–69.
[58] Sosnicki S, Kapral M, Weglarz L. Molecular targets of metformin antitumor action. Pharmacol Rep 2016;68:918–25.
[59] Fidan E, Onder Ersöz H, Yılmaz M, et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol 2011;48:297–302.
[60] Terrin N, Schmid CH, Lau J, et al. Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003;22:2113–26.